Imgatuzumab
EGFR-expressing solid tumors (e.g., Colorectal Cancer, HNSCC)
Phase 2Active
Key Facts
Indication
EGFR-expressing solid tumors (e.g., Colorectal Cancer, HNSCC)
Phase
Phase 2
Status
Active
Company
About Pega-One
Pega-One is a private, pre-revenue biotech focused on advancing next-generation antibody therapeutics for oncology. Its lead asset, Imgatuzumab, is a glycoengineered anti-EGFR monoclonal antibody designed to enhance Antibody-Dependent Cellular Cytotoxicity (ADCC) and Phagocytosis (ADCP), potentially improving efficacy over first-generation EGFR inhibitors. The company's strategy involves licensing and developing differentiated biologic candidates to address unmet needs in cancer care. As a relatively young company, its near-term value creation hinges on the clinical progress of its single, in-licensed asset.
View full company profile